ArticleEJNMMI radiopharmacy and chemistry2025
Fibroblast activation protein expression in the tumor microenvironment is crucial in survival prediction and differentiation of recurrent gliomas: a head-to-head comparison of
Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predicting the unpredictable: prognostic and predictive power of FAPI-PET imaging in oncology: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- The FAP-FDG Integration Score (FFIS): Development and prognostic validation of a dual-tracer PET phenotype for solid tumors.European journal of nuclear medicine and molecular imaging · 2026Article
- Is There an Added Value of Dual-Time-Point [Cancers · 2026Article
- Comparative Insights intoMolecular imaging and radionuclide therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe precise differentiation of recurrent glioma from treatment-related changes, such as pseudoprogression or radiation necrosis, is essential for treatment planning and remains a significant challenge. Fibroblast activation protein (FAP) expressed by cancer-associated fibroblasts can be targeted with PET tracers for in vivo visualization and quantification. This study aims to evaluate the diagnostic and prognostic effectiveness of FAP expression in patients with potential recurrent glioma by directly comparing [gallium-68] FAP inhibitor-04 and [fluorine-18] fluoroethyl-L-tyrosine PET/CT imaging. Thirty glioma patients showing signs of possible recurrence during routine MRI follow-up after treatment were enrolled. PET-based semiquantitative parameters, clinical factors, and survival data were collected for analysis.
resultsPaired comparison of SUVmax, TBRmax, MTV, and TLU originating from two PET imaging studies indicated significant differences in TBRmax, MTV, and TLU, with P values of 0.000, 0.001, and 0.000, respectively. Univariate logistic regression analysis revealed a marginally non-significant difference in efficacy (P = 0.053) of the initial pathological diagnosis. In multivariate logistic regression analysis, PET parameters, initial pathological data, age, and gender were used to develop the predictive models step by step. Although trends towards significance were observed in the MTV
conclusionsThis head-to-head exploratory study showed that glioma FAP expression volume is an independent risk factor that can significantly influence overall survival in patients with recurrent glioma. Although statistically insignificant, the MTV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.